Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045582 | 0.82 | EP300 (0.36) | EP300KAT2BKAT8APPALDH1A1 | |
| SCHEMBL2776293 | 0.78 | KDM4E (0.32) | ALDH1A1MAPTALOX15HSD17B10GAA | |
| SCHEMBL2490327 | 0.77 | ALDH1A1 (0.33) | ALDH1A1MAPTMEN1USP2LMNA | |
| SCHEMBL2079127 | 0.76 | KDM4E (0.31) | MAPTGAA | |
| SCHEMBL27606261 | 0.75 | EP300 (0.37) | EP300KAT2BKAT8APPALDH1A1 | |
| SCHEMBL27971633 | 0.74 | — | — | |
| SCHEMBL2319874 | 0.73 | GAA (0.32) | KMT2AGAA | |
| SCHEMBL8842929 | 0.73 | — | — | |
| SCHEMBL1704039 | 0.73 | — | — | |
| SCHEMBL27588553 | 0.72 | APP (0.36) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453783-B1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | AVENTIS PHARMA SA (FR) | 2006-10-04 | — | — | EP | claimed |
| US-6887904-B2 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-05-03 | — | — | US | claimed |
| EP-1453783-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | Aventis Pharma S.A. (FR) | 2004-09-08 | — | — | EP | claimed |
| US-20030176643-A1 | Ethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-18 | — | — | US | claimed |
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | US | claimed |
| US-6586630-B1 | Carbocyclic carboxy amines, used as motilin receptor antagonists for therapy of gastrointerstinal disorders such as irritable bowel syndrome; hormone inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-01 | — | — | US | claimed |
| WO-2003048096-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | AVENTIS PHARMA S.A. (FR) | 2003-06-12 | — | — | WO | claimed |
| EP-1116726-A1 | ETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-07-18 | — | — | EP | claimed |
| EP-1453783-B1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | AVENTIS PHARMA SA (FR) | 2006-10-04 | — | — | EP | disclosed |
| EP-1130017-B1 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMA CO LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6887904-B2 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-05-03 | — | — | US | disclosed |
| EP-1453783-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | Aventis Pharma S.A. (FR) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
| US-6720433-B2 | MOTILIN RECEPTOR ANTAGONIST; PHE-N-ME-VAL-(3-(3-METHYLINDOL-5-YL))ALA-NH2;PHE-N-ME-VAL-PHE( 3-ACETYL-4-HYDROXY)-NH2;PHE-N-ME-VAL-(3-(5-TERT-BUTYL-4-SULFAM OYL-2-FURYL))ALA-NH2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-13 | — | — | US | disclosed |
| EP-0934937-A1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998022103-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
| US-5677319-A | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5571803-A | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-11-05 | — | — | US | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176643-A1 | Ethylamine derivatives | MLNR, GIPR, MC4R | EP300 1437/4885KAT2B 2850/4885KAT8 2705/4885 |
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | ABL1, MCL1, AHR | EP300 305/4885KAT2B 1146/4885KAT8 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.